1
项与 CD19/CD20 CAR-T (Beijing DOING Biomedical technology Co.,ltd) 相关的临床试验Phase I Study of T Cells Expressing an Anti-CD19 and Anti-CD20 Bispecific Chimeric Receptor in Patients With B Cell Malignancies
This study aims to evaluate the safety, efficacy and duration of response of anti-CD19 anti-CD20 Bispecific Chimeric Antigen Receptor (CAR) redirected autologous T-cells in patients with high risk, relapsed CD19+ and CD20+ haematological malignancies.
100 项与 CD19/CD20 CAR-T (Beijing DOING Biomedical technology Co.,ltd) 相关的临床结果
100 项与 CD19/CD20 CAR-T (Beijing DOING Biomedical technology Co.,ltd) 相关的转化医学
100 项与 CD19/CD20 CAR-T (Beijing DOING Biomedical technology Co.,ltd) 相关的专利(医药)
100 项与 CD19/CD20 CAR-T (Beijing DOING Biomedical technology Co.,ltd) 相关的药物交易